News and Trends 5 Dec 2022 Positive antibody persistence for vaccine treating mosquito disease A single shot vaccine for mosquito-borne disease chikungunya has had positive antibody persistence data 12 months after vaccination. The primary endpoint also met with a 99% seroresponse rate. The disease is caused by the chikungunya virus (CHIKV), a Togaviridae virus, transmitted by Aedes mosquitoes. Following positive immunogenicity and safety data from a phase 3 study […] December 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2021 Valneva’s Inactivated Covid-19 Vaccine Aces Phase III Trial Last week, the French vaccine maker Valneva announced promising phase III trial results of its inactivated Covid-19 vaccine: a well-established technology that could confer broader immunity to the virus than shots currently on the market. Valneva’s vaccine candidate consists of a killed or ‘inactivated’ version of SARS-CoV-2, the virus responsible for Covid-19. The vaccine was […] October 26, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 19 Aug 2021 Chikungunya Vaccine First to Succeed in Phase III Trial In a significant step in the fight against tropical disease, the mosquito-borne viral disease chikungunya may become preventable with a new vaccine candidate from French biotech Valneva that just passed phase III trials. The results of the phase III trial revealed that a single dose of the live attenuated vaccine developed by Valneva induced the […] August 19, 2021 - 3 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jun 2021 The Top European Biotech Investment Rounds in May Last month saw huge biotech investment rounds dedicated to Covid-19 vaccines in Europe, including IPOs by Valneva and Vaccitech. However, a €227M (£195M) private round by the DNA sequencing giant Oxford Nanopore Technologies made the biggest splash. Last month was a difficult one for a number of public biotech companies. Biotech stock indices proved volatile […] June 10, 2021 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 May 2020 Lyme Disease Vaccine Gets Pfizer’s Backing in €284M Deal The French biotech Valneva will collaborate with Pfizer to develop and commercialize Valneva’s phase II-stage Lyme disease vaccine candidate. The deal they signed is expected to help compensate for the impact of the Covid-19 pandemic on Valneva’s financial outlook for 2020. The latest alliance will pool Valneva’s vaccine R&D expertise with Pfizer’s vast drug development […] May 7, 2020 - 4 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2019 Update: Single-Shot Vaccine for Chikungunya Lasts for a Year in Phase I Update (18/11/2019): French biotech Valneva has revealed additional phase I results concerning its experimental chikungunya vaccine; all 68 patients that were given a single injection of the vaccine showed sustained protection after 12 months. The company is currently running a phase II study and plans to launch a pivotal phase III trial next year. Update […] November 18, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 4 Sep 2019 Overcoming Clinical Setbacks to Fight Insect-Borne Diseases Sometimes things don’t go your way in the biotech industry. The CEO of Valneva, Thomas Lingelbach, shared his experience of migrating from big pharma to biotech, and how his first biotech company weathered phase III failures to develop vaccines for neglected diseases. Once confined to the less developed regions of the world, many insect-borne diseases […] September 4, 2019 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 20 Nov 2018 Phase I Gives Hope for First Zika Vaccine Results from a Phase I trial showed promising safety and efficacy of a potential first vaccine against the mosquito-borne Zika virus, developed by French biotech Valneva and US biopharma Emergent BioSolutions. In the US-based Phase I trial, 67 participants were injected with either placebo or inactivated forms of the virus as a vaccine. Two months later, […] November 20, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2016 French Biotech Puts a New Lyme Disease Vaccine on the Horizon There is currently no vaccine for the fast-growing disease in the US, & treatments cost over $1Bn every year. Valneva might have a vaccine to stem the tide. Valneva, a commercial-stage biotech based in Lyon, France, has just received clearance from the FDA and its European counterpart to begin clinical trials for its experimental Lyme Disease […] December 12, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email